ClinicalTrials.gg
CompletedNCT00393991Updated Jun 23, 2011

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

A Phase 3 interventional study of Fluticasone propionate/formoterol fumarate 100/10 and Fluticasone propionate 100 in Asthma, sponsored by SkyePharma AG. Completed at 57 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-06-23.

Sponsored by SkyePharma AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,695 studies in Asthma with a site in United States — 134 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
232nd of 1,353
475 · median 100
Started
2006
with 82 others
Phase 3
254 of 1,695
14 open now
Registered
222nd of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 232nd largest by enrollment of the 1,353 interventional ones that give a count, is one of 83 that started in 2006, is one of 254 in phase 3, and was the 222nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

134 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with mild to moderate asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Fluticasone Propionate
  • Formoterol Fumarate
  • Pressurized metered dose inhaler
  • Hydrofluoroalkane
  • Mild to Moderate Asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Ages eligible for study: 12 years and above; genders eligible for study: both; prior use: steroid-requiring or steroid-free.

Inclusion criteria

Inclusion Criteria:

  • History of asthma for at least 12 months.
  • For steroid-requiring patients, documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit
  • For steroid-free patients, no history of inhaled steroid asthma medication for at least 12 weeks prior to Screening Visit.
  • Demonstrate FEV-1 of 60-85% of predicted normal values at Screening and Baseline Visit.
  • Documented reversibility of 15% within 12 months of Screening or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration).
  • Symptoms of Asthma during Run-in
  • Females of must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile, or using acceptable methods of .
  • Must otherwise be healthy.
  • Provide written . Wishes of minors must be respected.

Exclusion criteria

Exclusion Criteria:

  • Life-threatening asthma within past year or during Run-In Period.
  • History of systemic medication within 3 months before Screening Visit.
  • History of omalizumab use within past 6 months.
  • History of leukotriene receptor antagonist use, e.g. montelukast, within past week.
  • Current evidence or history of any disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.
  • Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-In Period.
  • Significant, non-reversible, pulmonary disease (e.g., [COPD], cystic fibrosis, bronchiectasis).
  • Known (HIV)-positive status.
  • Smoking history equivalent to "10 pack years".
  • Current smoking history within 12 months prior to Screening Visit.
  • Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening Visit.
  • Patients who are confined in institution
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
475 participants (actual)

Study arms

  • Experimental
    1

    FlutiForm 100/10 μg

    Drug: Fluticasone propionate/formoterol fumarate 100/10

  • Active comparator
    2

    Fluticasone 100 μg

    Drug: Fluticasone propionate 100

  • Active comparator
    3

    Formoterol 10 μg

    Drug: Formoterol fumarate 10

  • Placebo comparator
    4

    Placebo

    Drug: Placebo

Interventions

  • DrugFluticasone propionate/formoterol fumarate 100/10

    FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

    Also known as: Flutiform 100/10

  • DrugFluticasone propionate 100

    Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.

    Also known as: SKP Fluticasone 100

  • DrugFormoterol fumarate 10

    Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

    Also known as: SKP Formoterol 10

  • DrugPlacebo

    Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.

    Also known as: SKP Placebo

06

What researchers measure

Primary outcomes

  1. Change in Forced Expiratory Volume in 1 s (FEV-1) over 12 weeks recorded in electronic diary. Discontinuation due to lack of efficacy

    Time frame: Week 0 and 12 visits

Secondary outcomes

  1. Other pulmonary function tests including forced vital capacity (FVC) and peak expiratory flow rate (PEFR).

    Time frame: Whole duration of study

  2. Clinical endpoints (frequency of asthma exacerbations and patient data captured in diary including daily morning and evening PEFR).

    Time frame: Whole duration of study

  3. Safety variables including adverse events, ECGs, clinical laboratory tests and vital signs.

    Time frame: Whole duration of study

  4. Serial 12-hour FEV-1 area under the curve (AUC).

    Time frame: Week 0, 2 and 12 visits

07

Study locations

57 sites
  • Research Site
    Pell City, Alabama 35128, United States
  • Research Site
    Scottsdale, Arizona 85251, United States
  • Research Site
    Cypress, California 90630, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Center
    Los Angeles, California 90048, United States
  • Research Site
    Mission Hills, California 91345, United States
  • Research Site
    Centennial, Colorado 80112, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Englewood, Colorado 80112, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Gainesville, Florida 32610, United States
  • Research Center
    Largo, Florida 33770, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Tallahassee, Florida 32308, United States
  • Research Site
    Conyers, Georgia 30012, United States
  • Research Site
    Lawrenceville, Georgia 32308, United States
  • Research Site
    Round Lake Beach, Illinois 60073, United States
  • Research Site
    Indianapolis, Indiana 46208, United States
  • Research Site
    Bethesda, Maryland 20814, United States
  • Research Site
    Brockton, Massachusetts 02301, United States
  • Research Site
    Cherry Hill, New Jersey 08003, United States
  • Research Site
    Forked River, New Jersey 08732, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Center
    Elizabeth City, North Carolina 27909, United States
  • Research Site
    Elizabeth City, North Carolina 27909, United States
  • Research Site
    Columbus, Ohio 43235, United States
  • Research Site
    Toledo, Ohio 43617, United States
  • Research Site
    Okalahoma City, Oklahoma 73139, United States
  • Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Research Site
    Oklahoma, Oklahoma 73104, United States
  • Research Site
    Eugene, Oregon 97401, United States
  • Research Site
    Lake Oswego, Oregon 97035, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Philadelphia, Pennsylvania 19115, United States
  • Research Site
    Pittsburgh, Pennsylvania 15241, United States
  • Research Site
    Scranton, Pennsylvania 18509, United States
  • Research Site
    Austin, Texas 78750, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    El Paso, Texas 79925, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    Round Rock, Texas 78681, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Bellingham, Washington 98225, United States
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Mississauga, Ontario L5B 1N1, Canada
  • Research Site
    Ottawa, Ontario K1Y 4G2, Canada
  • Research Site
    Point Edward, Ontario N7V 1X4, Canada
  • Research Site
    Sudbury, Ontario P3A 1Y8, Canada
  • Research Site
    Sudbury, Ontario P3A1Y8, Canada
  • Research Site
    Toronto, Ontario M5S 2A5, Canada
  • Research Site
    Toronto, Ontario M6H 3M2, Canada
  • Research Site
    St. Romuald, Quebec G6W 5M6, Canada
  • Research Site
    St. John's, A1B 4S8, Canada
08

References and documents

Publications

  • Nathan RA, D'Urzo A, Blazhko V, Kaiser K. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med. 2012 Oct 18;12:67. doi: 10.1186/1471-2466-12-67. PubMed 23078148 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2006
First posted
Oct 31, 2006
Start
Jul 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results delay requested
Aug 24, 2010
Last update
Jun 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00393991
Lead sponsor
SkyePharma AG
First posted
Oct 31, 2006
Start date
Jul 2006
Primary completion
Apr 2008
Completion
Apr 2008
Last update
Jun 23, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion